glp-1 compound news 🚨 FDA Moves to Shut Down Mass-Market Compounded GLP-1s The FDA is taking action to restrict widely marketed, non–FDA-approved compounded products, citing concerns over safety, quality, and misleading claims. As demand FDA Shares Safety Data About

However, our results revealed impaired recognition memory in males, while females remained unaffected

Study methods: Adult patients who were taking GLP-1s and scheduled to receive anesthesia at 3 hospitals between June 30, 2023, and August 15, 2024, were evaluated via preoperative point-of-care gastric ultrasonography (GUS)

Contact Us Important Notice This page is for general informational purposes only and does not constitute legal or medical advice

We appreciate your support

Measured across patients engaged with Nourish for 12 months with obesity (BMI 30), diabetes (A1C 6.5), high cholesterol (LDL 130), and hypertension (SBP 140) Our patients have complex health needs Nourish supports patients with chronic conditions - including cardiometabolic conditions

DrMR: Power of the gut